D-1553 is an orally administered anti-tumor drug independently developed by Yifang Biotech. It is the first domestic drug targeting the KRAS-G12C gene mutation to be approved for clinical trials. In preclinical studies, D-1553 demonstrated excellent tumor-suppressive effects and good safety profiles. The drug was approved by the U.S. FDA in October 2020, and Phase I clinical trials have been launched in countries and regions including the United States, Australia, Taiwan (China), and South Korea. The progress has been smooth, and in January 2021, D-1553 received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China to initiate Phase I/II clinical trials.

If you are interested in participating in this clinical trial, please contact Professor Zhang at: 19542809800.

This clinical trial is being conducted under the leadership of Professor Lu Shun, Director of the Department of Oncology at Shanghai Jiao Tong University Affiliated Chest Hospital, across multiple hospitals in China (listed below):

• Shanghai Chest Hospital, Department of Oncology
• Shanghai Chest Hospital, Department of Respiratory Medicine
• Zhejiang Provincial Cancer Hospital
• The Second Affiliated Hospital of Zhejiang University School of Medicine
• Hunan Provincial Cancer Hospital
• Henan Provincial Cancer Hospital
• Chongqing Cancer Hospital
• The First Affiliated Hospital of Ningxia Medical University